Applications of N-Boc-L-Lysine Methyl Ester Hydrochloride in Industrial Manufacturing

As a specialized manufacturer, we supply N-Boc-L-Lysine Methyl Ester Hydrochloride to process-intensive sectors with established protocols and stringent quality benchmarks. The following applications highlight how downstream industries leverage this protected amino acid derivative within strictly defined workflows, regulatory environments, and formulation parameters.

1. Peptide Active Pharmaceutical Ingredient (API) Synthesis

Major pharmaceutical API manufacturers use N-Boc-L-Lysine Methyl Ester Hydrochloride as a protected lysine derivative in solid-phase and solution-phase peptide syntheses. Its methyl ester group delivers required selectivity during sequence assembly, while the Boc group ensures amino-side chain protection throughout complex coupling processes. Production routes rely on this intermediate for high-fidelity chain elongation in both clinical and commercial peptide manufacturing, especially for injectable peptides containing lysine residues.

Industry compliance standards

• United States Pharmacopeia (USP) Peptide APIs
• European Pharmacopoeia (EP) 2.9.45 (Peptide Purity)
• ICH Q7 GMP for Active Pharmaceutical Ingredients
• FDA 21 CFR Part 211 (Finished Pharmaceuticals)

Typical usage ratio

• 1.05–1.15 molar equivalents per lysine residue in peptide chain; excess adjusted based on chain length and resin capacity to minimize deletion sequences.

Downstream process integration

• Integrated at the protected amino acid charging step on solid supports or during solution phase after initial chain-loading. Deprotection and coupling monitored by HPLC for residual protecting groups and full sequence assembly prior to final cleavage and purification.

Final product types

• Therapeutic peptides for parenteral drugs
• GMP peptide generics
• Investigational new drug (IND) peptides
• Contract-manufactured oligopeptides supplied to pharmaceutical companies

2. Specialty Enzyme Modification

Enzyme formulation groups in biocatalysis deploy this derivative when introducing site-specific protected lysine functionalities into target proteins during mutagenesis and modification cycles. Controlled modification with a Boc group enables them to safeguard amine reactivity during protein folding or chemical ligation steps. This methodology supports the engineering of enzymes used in synthesis of fine chemicals, diagnostic reagents, and advanced biotechnological intermediates.

Industry compliance standards

• ISO 13485:2016 (Medical Devices—Quality Management in Enzyme Production)
• EN ISO 9001:2015 (Quality Management Systems)
• OECD Guidelines for Chemical Synthesis (as applicable to research-use enzymes)

Typical usage ratio

• 0.5–2 molar equivalents per available lysine residue, optimized by enzyme structure and degree of site-directed modification; adjustment conducted via pilot-scale activity assays.

Downstream process integration

• Introduced during pre-folding modification in recombinant protein purification pipelines or after primary folding for late-stage chemical modification. Removal of the Boc protecting group completed prior to functional assessment or downstream conjugation.

Final product types

• Customized biocatalysts for pharmaceutical synthesis
• Immobilized enzymes for industrial reactors
• Diagnostic enzymes for immunoassays
• Reagent-grade enzymes sold for specialty research

3. Protected Lysine Building Block for Complex Chemical Synthesis

Advanced chemical synthesis platform operators utilize N-Boc-L-Lysine Methyl Ester Hydrochloride in fragment coupling protocols to introduce protected lysine motifs within non-peptidic macromolecules or for constructing peptidomimetics. These process flows demand highly selective amino group protection to avoid side reactions when building heterocyclic compounds, modified biopolymers, or pre-drug molecules (prodrugs).

Industry compliance standards

• ISO 9001:2015 (Quality system for chemical intermediate production)
• REACH Regulation (EC) No 1907/2006 (if applicable for EU-supplied chemicals)
• Controlled Substances Regulations (if fragments used in pharmaceutical R&D)

Typical usage ratio

• Equimolar to slight molar excess (1.0–1.2 equivalents) relative to functional group count required in custom synthesis; stoichiometry depends on target compound structure and desired yield scale.

Downstream process integration

• Charged at the block assembly or elongation stage in convergent or linear synthesis routes; typically introduced before key bond-forming steps requiring amine suppression, removed during global deprotection under acidic conditions.

Final product types

• Pharmaceutical-grade peptidomimetics
• NCE (new chemical entity) intermediates
• Functionalized polymers featuring lysine motifs
• Drug-linked macromers for targeted delivery systems

4. Intermediate for Research-Grade Peptide Reagent Manufacturing

Producers of peptide reagents for molecular biology and analytical research employ this derivative to custom-synthesize peptides containing protected lysine for chemical labeling, cross-linking studies, or bioactivity investigations. Its inclusion as a protected building block provides reliable handling and storage, facilitating clean removal of protecting groups after the bulk of synthetic manipulation, suiting workflows that require high-purity, sequence-defined peptides for downstream application in R&D environments.

Industry compliance standards

• ISO 9001:2015 (Quality Management for Research Chemicals)
• OECD Good Laboratory Practice (GLP) for non-clinical research reagents
• REACH Annex IV & V (applicable exclusions for research-use chemicals)

Typical usage ratio

• 1.0–1.1 equivalents per lysine unit in target sequence; minor excess employed to limit incomplete coupling in micro-scale peptide synthesis workflows.

Downstream process integration

• Incorporated at resin-charging or solution-phase synthesis setup; used throughout iterative elongation and cleavage operations, with final global deprotection preceding product lyophilization and QC analysis (HPLC, MS, purity assessment).

Final product types

• Purified synthetic peptides for laboratory assays
• Chemical labeling and bioconjugation targets
• Peptide substrates for enzymatic activity screening
• Affinity tags and cross-linkers for protein interaction studies